Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PR Newswire - Thu May 14, 7:15PM CDT

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC). Such investors are advised...

ORIC : 8.41 (+5.52%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PR Newswire - Thu May 7, 9:00AM CDT

NEW YORK , May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc.  ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.41 (+5.52%)
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates GlobeNewswire - Mon May 4, 3:05PM CDT

Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026 Reported rinzimetostat...

ORIC : 8.41 (+5.52%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It? Barchart - Sun May 3, 4:00PM CDT

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.41 (+5.52%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It? Barchart - Sat May 2, 4:00PM CDT

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.41 (+5.52%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It? Barchart - Fri May 1, 4:09PM CDT

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 8.41 (+5.52%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 1, 3:30PM CDT

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...

ORIC : 8.41 (+5.52%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PR Newswire - Thu Apr 30, 9:40PM CDT

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.41 (+5.52%)
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire - Fri Apr 17, 3:05PM CDT

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 8.41 (+5.52%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC PR Newswire - Thu Apr 16, 9:00AM CDT

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 8.41 (+5.52%)

Barchart Exclusives

Berkshire Hathaway Gave Up on This Underperforming Dividend Stock, But It May Be Time for You to Buy the Dip Barchart - Wed May 20, 6:30PM CDT
Berkshire Hathaway dumped its stake in Domino's Pizza in Q1. The stock has a healthy dividend yield of 2.6% and is trading at reasonable valuations though. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.